but the Seattle-based biotech company has staged a miracle comeback. CEO Bob Kirkman talked about how he plans to deploy his newfound resources in the year ahead, during this exclusive interview.
—Bothell, WA-based AVI Biopharma (NASDAQ: [[ticker:AVII]]) offered an early peek at clinical trial results for its targeted therapy against Duchenne Muscular Dystrophy. This set of data is still quite preliminary, but AVI saw some encouraging signs that it is able to stimulate production of the dystrophin protein that boys with this genetic disease lack.
—We have been rolling out a batch of fascinating guest editorials from Xconomists and other technology leaders around the country, who are offering their thoughts on the biggest innovations of the decade in their respective fields. Cliff Reid, who runs an OVP-backed company that wants to sequence entire human genomes for $5,000 or less, gave his view on the five big advances in decade of the genome; Nobel laureate Phil Sharp of MIT wrote about the biggest biomedical discovery of the decade; and San Diego venture capitalist Larry Bock offered his view on the 10 biggest innovations from a variety of fields. Don’t worry, we have plenty of Seattleites scheduled to weigh in over the coming weeks.
—And last, but not least, we had another feisty guest editorial from Charlotte Hubbert, the Kauffman Fellow at Seattle-based Accelerator. Now’s the time for VCs to go back to the old school, and invest in truly disruptive technologies, Hubbert says.
